Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1964 1
1965 4
1966 3
1967 3
1968 2
1969 3
1970 1
1971 1
1973 2
1974 1
1975 2
1976 1
1977 4
1978 7
1980 3
1981 5
1982 9
1983 3
1984 8
1985 8
1986 8
1987 4
1988 5
1989 6
1990 7
1991 5
1992 7
1993 3
1994 5
1995 5
1996 11
1997 7
1998 16
1999 9
2000 5
2001 6
2002 4
2003 8
2004 12
2005 7
2006 9
2007 15
2008 11
2009 13
2010 9
2011 10
2012 15
2013 14
2014 20
2015 20
2016 21
2017 22
2018 27
2019 30
2020 27
2021 21
2022 37
2023 24
2024 26
2025 30
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

565 results

Results by year

Filters applied: . Clear all
Page 1
Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A, Yang XC, Barca T, Lucas A, Turkoz M, Wong JTS, Nishimoto KP, Brodey MM, Tabrizizad M, Gundurao SRY, Bai L, Bhat A, An Z, Abbot S, Satpayev D, Aftab BT, Herrman M. Makkouk A, et al. Among authors: nishimoto kp. J Immunother Cancer. 2021 Dec;9(12):e003441. doi: 10.1136/jitc-2021-003441. J Immunother Cancer. 2021. PMID: 34916256 Free PMC article.
Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025.
Tanabe A, Katabami T, Hashimoto S, Izawa S, Ichijo T, Otsuki M, Oriuchi N, Kinuya S, Kinoshita H, Kimura N, Shibata H, Sone M, Takahashi K, Takizawa N, Takekoshi K, Tsuiki M, Tanase-Nakao K, Nakamura Y, Nishimoto K, Hasegawa T, Murakami M, Yonamine M, Naruse M. Tanabe A, et al. Among authors: nishimoto k. Endocr J. 2026 Jan 6;73(1):115-157. doi: 10.1507/endocrj.EJ25-0165. Epub 2025 Oct 10. Endocr J. 2026. PMID: 41083371 Free PMC article.
Cutaneous mucormycosis.
Mizutari K, Nishimoto K, Ono T. Mizutari K, et al. Among authors: nishimoto k. J Dermatol. 1999 Mar;26(3):174-7. doi: 10.1111/j.1346-8138.1999.tb03450.x. J Dermatol. 1999. PMID: 10209925
The Effectiveness and Safety Profile of Nivolumab-Plus-Ipilimumab in Previously Untreated Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma (J-ENCORE Study).
Nishimoto K, Kimura G, Sazuka T, Hamamoto S, Nozawa M, Numakura K, Mizokami A, Kondo T, Naito S, Abe T, Ohba K, Nagata M, Onodera S, Ito H, Uemura H. Nishimoto K, et al. Int J Urol. 2025 Aug;32(8):961-972. doi: 10.1111/iju.70076. Epub 2025 Apr 24. Int J Urol. 2025. PMID: 40271863 Free PMC article.
Immunology of gangliosides.
Ravindranath MH, Gonzales AM, Nishimoto K, Tam WY, Soh D, Morton DL. Ravindranath MH, et al. Among authors: nishimoto k. Indian J Exp Biol. 2000 Apr;38(4):301-12. Indian J Exp Biol. 2000. PMID: 11218805 Review.
Prognostic significance of circulating tumor DNA alterations in advanced renal cell carcinoma from SCRUM-Japan MONSTAR-SCREEN: a nationwide genomic profiling project.
Kato T, Shiota M, Nishimoto K, Matsubara N, Osawa T, Abe T, Yasumizu Y, Tanaka N, Yamamoto Y, Ishizuya Y, Abutani H, Bando H, Fujisawa T, Nakamura Y, Oya M, Shinohara N, Eto M, Yoshino T, Nonomura N. Kato T, et al. Among authors: nishimoto k. Br J Cancer. 2025 Jul;133(1):111-120. doi: 10.1038/s41416-025-02985-8. Epub 2025 May 5. Br J Cancer. 2025. PMID: 40325148 Free PMC article.
Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial.
Inui N, Suzuki T, Tanaka K, Karayama M, Inoue Y, Mori K, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Matsuura S, Nishimoto K, Matsui T, Asada K, Hashimoto D, Fujii M, Niwa M, Uehara M, Matsuda H, Koda K, Ikeda M, Inami N, Tamiya Y, Kato M, Nakano H, Mino Y, Enomoto N, Suda T. Inui N, et al. Among authors: nishimoto k. J Clin Oncol. 2024 Aug 10;42(23):2780-2789. doi: 10.1200/JCO.24.00278. Epub 2024 Jun 4. J Clin Oncol. 2024. PMID: 38833659 Free PMC article. Clinical Trial.
Reevaluating the therapeutic role of extended lymph node dissection in the era of robot-assisted radical prostatectomy.
Sawada A, Nishimoto K, Akamatsu S, Kubota M, Sumiyoshi T, Saito R, Kurahashi R, Sekine Y, Negoro H, Shiraishi Y, Iguchi R, Nakashima M, Kokura K, Iwamura H, Kohei N, Shimatani K, Kamoto T, Kobayashi T, Goto T; Daimonji Clinical Application Database (Dai-CAD) study group. Sawada A, et al. Among authors: nishimoto k. Sci Rep. 2025 May 21;15(1):17680. doi: 10.1038/s41598-025-00926-2. Sci Rep. 2025. PMID: 40399311 Free PMC article.
565 results